Table 1 Characteristics of study participants at baseline.

From: Effects of elevated serum urate on cardiometabolic and kidney function markers in a randomised clinical trial of inosine supplementation

 

Placebo (n = 60)

Inosine (n = 60)

Age (years)

68.8 (1.9)

68.2 (2.3)

Ethnicity, n (%)

NZ European

59 (98%)

58 (97%)

NZ Māori

1 (2%)

0

NZ Asian

0

2 (3%)

Serum urate

mmol/L

0.28 (0.06)

0.27 (0.06)

mg/dL

4.7 (1.0)

4.5 (1.0)

Weight (kg)

72.4 (12.6)

67.5 (10.9)

Body mass index (kg/m2)

27.3 (4.7)

26.1 (4.2)

Waist circumference (cm)

89 (12)

85 (11)

Systolic blood pressure (mmHg)

136 (17)

134 (18)

Diastolic blood pressure (mmHg)

73 (8)

72 (10)

LDL cholesterol (mmol/L)

3.0 (0.9)

3.2 (0.8)

HDL cholesterol (mmol/L)

1.8 (0.4)

1.9 (0.5)

Triglycerides (mmol/L)

1.0 (0.4)

1.0 (0.4)

C-reactive protein (mg/L)

2.3 (2.5)

2.0 (1.9)

Fasting glucose (mmol/L)

5.0 (0.5)

4.9 (0.4)

HbA1c (mmol/mol)

37 (3)

36 (3)

Insulin (mU/L)

8.7 (4.1)

7.8 (3.4)

FEUA (%)

8.0 (3.1)

8.0 (2.7)

Creatinine (µmol/L)

63.3 (8.6)

62.5 (8.7)

eGFR (mL/min/1.73 m2)

91 (15)

92 (14)

  1. Unless otherwise stated, data are presented as mean (SD). Baseline demographic values, weight, body mass index, serum creatinine, and serum urate have been reported previously10.
Back to article page